SOLAR-1: A phase III study of alpelisib + fulvestrant in men and postmenopausal women with HR+/HER2– advanced breast cancer (BC) progressing on or after prior aromatase inhibitor therapy.

Authors

Fabrice Andre

Institut Gustave Roussy, Villejuif, France

Fabrice Andre , Mario Campone , Eva M. Ciruelos , Hiroji Iwata , Sibylle Loibl , Hope S. Rugo , Celine Wilke , David Mills , Marie Chol , Anne-Sophie Longin , Dejan Juric

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

A phase 3 study of alpelisib (ALP) plus fulvestrant (FUL) in men and postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) ABC progressing on or after aromatase inhibitor (AI) therapy: SOLAR-1.

First Author: Hope S. Rugo

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1).

First Author: Sara A. Hurvitz

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

A phase II, single-arm, non-randomized study of alpelisib (BYL719) in combination with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (btcrc-BRE19-409).

First Author: Cristina I. Truica

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), PIK3CA-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL).

First Author: Dejan Juric